Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2025 earnings at ($2.68) EPS.

ARWR has been the topic of a number of other research reports. Cantor Fitzgerald reissued an overweight rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday, June 20th. The Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a neutral rating and a $31.00 price objective on the stock. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a sell rating in a report on Tuesday, July 16th. Morgan Stanley reduced their price objective on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an equal weight rating for the company in a research note on Monday, May 13th. Finally, Chardan Capital reaffirmed a buy rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Hold and an average price target of $43.25.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $28.94 on Tuesday. The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of -6.81 and a beta of 0.94. Arrowhead Pharmaceuticals has a 1-year low of $20.67 and a 1-year high of $39.83. The company has a 50-day moving average of $25.80 and a 200 day moving average of $27.97.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. Arrowhead Pharmaceuticals’s revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 earnings per share. On average, equities analysts anticipate that Arrowhead Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares in the company, valued at approximately $704,078.55. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the transaction, the director now owns 30,205 shares in the company, valued at approximately $704,078.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the completion of the sale, the insider now owns 127,107 shares in the company, valued at approximately $3,213,264.96. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its holdings in Arrowhead Pharmaceuticals by 42.5% in the second quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 354 shares during the period. SG Americas Securities LLC raised its position in Arrowhead Pharmaceuticals by 27.4% during the second quarter. SG Americas Securities LLC now owns 9,369 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 2,014 shares during the period. Virtu Financial LLC purchased a new position in Arrowhead Pharmaceuticals during the first quarter valued at $269,000. Comerica Bank increased its stake in shares of Arrowhead Pharmaceuticals by 11.2% during the first quarter. Comerica Bank now owns 48,312 shares of the biotechnology company’s stock worth $1,382,000 after purchasing an additional 4,855 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Arrowhead Pharmaceuticals by 14.1% during the 1st quarter. California State Teachers Retirement System now owns 122,486 shares of the biotechnology company’s stock worth $3,503,000 after purchasing an additional 15,136 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.